As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.
Lung-MAP Protocol Expands Trial Access for Marginalized Groups miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.
Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.